Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance

Over the last decade, first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) (erlotinib and gefitinib) for the treatment of advanced non-small-cell lung cancer (NSCLC), especially adenocarcinoma, have demonstrated remarkable advances and leaded to improvement in patients’ survival time, either progression-free survival or overall survival. EGFR-TKI therapies also provided a superior quality of life in specific patient populations (1).